MedTrace Logo

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

NCT00281515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2012-06-29

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin in primary treatment of patients with epithelial ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Lonafarnib

100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day

Sponsors & Collaborators

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Werner Meier, Prof. Dr. · Ev. Krankenhaus, Düsseldorf, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00281515 on ClinicalTrials.gov